News

Translate this page RSS Share this page Print this page

SEARCH CRITERIA

DATE RANGE
to
 
King & Spalding Takes Major Role at CBI’s 10th Annual Pharmaceutical Compliance Congress


23 Jan 2013
THOUGHT LEADERSHIP

WASHINGTON, January 23, 2013 Five King & Spalding lawyers are set to participate in The Center for Business Intelligence’s 10th Annual Pharmaceutical Compliance Congress in Washington, D.C., on January 29. King & Spalding is a sponsor of the event.

This premier life science compliance forum brings together in-house counsel, compliance officers and other pharmaceutical manufacturer personnel to share best practices in all facets of compliance.

“As the federal government continues to pursue investigations and announce large-dollar settlements for healthcare fraud enforcement, compliance professionals are continually working to better their internal processes, oversight and strategy to propel corporate compliance programs forward and instill a culture of ethics and integrity across their organizations,” said Michael Petty, a King & Spalding partner participating in the forum. “Best practices are ever-evolving and the Pharmaceutical Compliance Congress will unite senior-level executives to share innovative efforts, lessons learned and compliance successes.”

Four King & Spalding lawyers will provide a post-election update titled “The Next 4 Years – What to Expect Post-Elections from Congress, the States, FDA and CMS ”:

  • Seth H. Lundy, partner, deputy leader, FDA and life sciences practice
  • Former Maryland Gov. Robert L. Ehrlich, Jr., senior counsel, government investigations and public policy practice
  • Michael Petty, partner, FDA and life sciences practice; former associate chief counsel for enforcement, FDA; and former vice president of development and regulatory law, Amgen Inc.
  • Mark D. Polston, partner, healthcare practice; former deputy associate general counsel for litigation, CMS division, Department of Health and Human Services Office of General Counsel

In addition, King & Spalding FDA and life sciences partners Marian Lee and Michael Petty will lead a breakout session on compliance considerations related to clinical research and pre-approval communications, titled “Communication Strategies during Pre-Approval and Pre-Launch – How to Treat Emerging Clinical Data.”

For more information about the event, click here.

About King & Spalding
Celebrating more than 125 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 800 lawyers in 17 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.

PEOPLE

OFFICES
Washington, D.C.